Status:
COMPLETED
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Lead Sponsor:
Incyte Corporation
Conditions:
Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) of 17 to 40 kg/m2
- Subjects must have two comparable psoriatic lesions measuring between 9 and 100 cm2 and these target lesions must be similar in size to each other, and separated by at least 15 cm.
Exclusion
- Subjects with lesions solely involving the palms of the hands or soles of the feet or intertriginous areas, the scalp or the face.
- Subjects with pustular psoriasis or erythroderma.
- Subjects currently on other topical agents or UVB therapy within 2 weeks of the first dose of study medication.
- Subjects receiving PUVA within 4 weeks of the first dose of study medication.
- Subjects receiving systemic retinoids, etanercept, adalimumab or efalizumab or oral immunosuppressives within 3 months prior to the first dose of study medication.
- Subjects receiving any other biological therapy (infliximab, alefacept, abatacept, etc) within 3 months of the first dose of study medication.
Key Trial Info
Start Date :
May 31 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2009
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00820950
Start Date
May 31 2007
End Date
April 30 2009
Last Update
February 8 2022
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Vallejo, California, United States
2
Boston, Massachusetts, United States
3
Rochester, New York, United States
4
Stony Brook, New York, United States